The majority of drugs are designed to block one specific function of a disease-causing protein. But over 80% of human proteins are not accessible via this approach and are generally considered “undruggable”. Although many important drivers of disease have been known for decades, they are simply out of reach of classical pharmacology.


molecular glue

leading the way into uncharted chemical space

At Proxygen, we specialize in a completely different class of drugs, called molecular glue degraders. Instead of merely inhibiting a harmful protein’s function, molecular glue degraders eliminate the protein completely. They do this by reprogramming the natural protein recycling machinery present in every cell.


target space

target selectivity

duration of effect



discovery platform

redefining treatments for previously
untreatable diseases

The immense potential of molecular glue degraders is best exemplified by Revlimid® and Pomalyst®, which have revolutionized the treatment of multiple myeloma. However, their discovery was completely fortuitous. Replicating their success has been hindered by a lack of rational drug discovery strategies for molecular glue degraders.

Now, for the first time, Proxygen’s innovative discovery platform is powering the development of novel glue degraders at scale.


developing the drugs of tomorrow with the tools of today

Our discovery and development of novel molecular glue degraders is made possible by a highly interdisciplinary approach: only by combining cutting-edge functional genomics, proteomics, and medicinal chemistry can we deliver transformative treatments to patients. At its core, a platform of cellular screens in disease-relevant models allows us to identify molecules that are active where it matters: inside diseased cells.